<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398840/" ref="ordinalpos=372&amp;ncbi_uid=4122754&amp;link_uid=PMC3398840" image-link="/pmc/articles/PMC3398840/figure/F6/" class="imagepopup">Figure 6.  From: Inhibition of Carcinoma Cell Motility by Epoxyeicosatrienoic Acid (EET) Antagonists. </a></div><br /><div class="p4l_captionBody">A proposed diagram of signaling pathway for EET-mediated prostate carcinoma cell motility. EET = epoxyeicosatrienoic acids; EETR = putative EET receptor, EEZE; EET antagonists; EGFR = epidermal growth factor receptor, HB-EGF = Heparin-binding EGF-like growth factor; MMPs = matrix metalloproteinases. PI3K/Akt = phosphatidylinositol 3-kinase/Akt signaling pathway, Pro = Pro-HB-EGF. In this proposed signaling pathway, EETs bind to a putative EETR to activate MMPs and cleave pro-HB-EGF to HB-EGF. Then, HB-EGF activates EGFR(30,31) and initiate signaling cascade to activate PI3K/Akt pathway to increase cell motility. An unidentified mechanism of EET-activated EETR to activate PI3K/Akt signaling pathway(32) cannot be ruled out.</div></div>